Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2014-02-04 Director's Dealing
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2014-02-04 English
Major Shareholding Notification 2014
Major Shareholding Notification
2014-01-29 English
FORM S-3ASR
Capital/Financing Update Classification · 100% confidence The document is a Form S-3ASR registration statement filed with the SEC, which is a shelf registration statement used by companies to register securities for sale to the public. It includes detailed information about the securities to be offered, the company, risk factors, and the plan of distribution. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not a brief announcement or certification, so it is not RNS or RPA.
2014-01-24 English
FORM 10-Q
Interim / Quarterly Report Q3 2013
2013-11-12 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated October 29, 2013, by Novavax, Inc. It reports the entry into an amendment to a Master Services Agreement with Cadila Pharmaceuticals Limited. The content focuses on a material definitive agreement amendment and includes an exhibit of the amendment. There are no financial statements, earnings data, or management discussion. The document is a current report on a material event, typical of Form 8-K filings, which are regulatory filings to disclose significant corporate events. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 3149 characters, which is short and consistent with a regulatory announcement rather than a full report.
2013-10-30 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions the closing of a public offering of common stock and the exercise of an overallotment option by underwriters. It includes a press release about the offering and a legal opinion on the issuance of the stock. There are no financial statements or detailed financial results presented, nor is this an annual or quarterly report. The content is focused on a capital raising event and related legal documentation. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive information about the financing event itself, not just an announcement of a report publication, so it is not an RPA. Confidence is high due to clear references to the offering and underwriting details.
2013-09-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.